A-TANGO Project

👏 3 more outstanding posters 📣 from the coordinating institute UCL at #EASLCongress 2026 - great job, Supacha & Jinxia! 1️⃣ Ammonia-induced bioenergetic failure via #TLR4🔋 2️⃣ YAQ006 and YAQ005 reduce mortality in #ACLF☠️ 3️⃣ Yaq-001 ameliorates liver injury via gut #microbiome🦠 @rajivjalan.bsky.social

💫 Three outstanding Charité posters at #EASLCongress 2026 in Barcelona - well done, Sina, Joscha & Alex! 1️⃣ Body composition & survival in HRS-AKI 2️⃣ Macrophages & gut barrier failure in alcoholic hepatitis🍷 3️⃣ Thrombin generation🩸in #cirrhosis & #ACLF @easlnews.bsky.social @europeliver.bsky.social

🧪 A deep dive into basic & translational science: Minneke Coenraad (LUMC) chaired today's last #PosterTour on "Experimental and Pathophysiology" at the Cirrhosis & Complications Track Hub! 💫 Meiqian Hu from Rajiv Jalan's group (UCL) did a fantastic job presenting her poster! #EASLCongress #EASL2026

🤩 Great attendance & active discussion at #EASLCongress today! Very insightful & interactive Networking Session on the evolving definition and #RiskStratification of ACLF, highlighting the new #ATANGOscore & the urgent need for international #Harmonisation of #ACLF criteria. @rajivjalan.bsky.social

At today’s J Hep Symposium, Benedikt Hofer (author) & Annalisa Berzigotti (challenger) discussed abstinence-induced #Recompensation in #Alcohol-related #Cirrhosis, chaired by Frank Tacke (Charité). 👉 Sustained abstinence = lower mortality 🍷⛔ #EASLCongress #LiverDisease @jhepatology.bsky.social

📣 SNEAK PEEK 🔍 of posters, talks, networking sessions & chairing activities by Consortium Members during #EASLCongress next week (27-30 May 2026) in Barcelona! #ACLF #cirrhosis #LiverDisease #LiverFailure #Hepatology #LiverSky @rajivjalan.bsky.social @europeliver.bsky.social @easlnews.bsky.social

🥳 How are you planning to celebrate #WorldLiverDay? And what do you do to strengthen your own liver? #SolidHabitsStrongLiver 👉 Eat healthy - daily 🥦 👉 Move your body - daily 🥎🎾🏃‍➡️ 👉 Reduce alcohol - always🍷 ➡️ 🥛 (there is no "safe" amount of alcohol) 👉 Get your liver checked regularly by a doctor 🩺

🚀 Motivation boost to kick off the new year 🙂: The European Commission agreed to provide a 6-month-long extension to A-TANGO! Let's use this momentum and move forward swiftly now, so that A-TANGO can bring the much-needed G-TAK therapy for severe #AlcoholicHepatitis #cirrhosis #ACLF to the market.

🥂 We have good news for the holidays: The technical hold-up in the EU portal has finally been resolved & we submitted the 3rd #PeriodicReport ☺️ Wishing everyone relaxing holidays❄️ Together, we are moving from bench to bedside to bring innovative therapies to #ACLF patients @rajivjalan.bsky.social

What an inspiring 9th Steering Committee Meeting! It was lovely to meet fellow liver-health enthusiasts & clinical investigators who recently joined the #GTAK Study. Let's include as many #ACLF patients in the study as possible.💉😊 #AlcoholicHepatitis @europeliver.bsky.social @easlnews.bsky.social

Join this exciting event! Don't miss our #OpenInnovation event, uniting experts in #DrugDevelopment, #bioinformatics, and #hepatology. Connect with researchers, industry professionals, and investors to share insights & explore collaboration opportunities! 🚀 Register now: inevent.uk/en/Crowdheli...

✅ How to reach a #consensus in science 🧬: Clinic director Frank Tacke (Charité) trains future #hepatology leaders on the #DelphiMethod, a reliable forecasting method using multiple rounds of questionnaires for an expert panel to reach a mutual agreement. 🗓️ What a fun #workshop at #EASLCongress 2025

👏 Fantastic job by Annarein Kerbert, LUMC, + Julian Pohl, Charité, at today's #networking session at #EASLCongress 👉 Is #alcohol-related #hepatitis in ACLF its own beast? 👉 Is systemic #inflammation the puppet master pulling #ACLF’s strings in booze-related hepatitis? Chair @rajivjalan.bsky.social

👑 The crown belongs to Julian Pohl for one of this year's TOP #Posters at #EASLCongress - Wow! 👏 🥳 TOP-217-YI 🥳 Pathophysiological basis of #ACLF triggered by #alcohol-related #hepatitis or #infection using circulating biomarkers of #inflammation, circulatory dysfunction & #albumin modifications

Big crowd at the #ACLF & Critical Illness #PosterTour at #EASLCongress: FRI-197 The AMMON-OHE model predicts #liver-related #complications in #outpatients with #cirrhosis: A prospective cohort study of the #AMMON consortium Crucial for understanding the disease progression! @rajivjalan.bsky.social

🌟 POSTER THU-182 by Supachaya S. (UCL, @rajivjalan.bsky.social) featured in a #PosterTour at #EASLCongress! 👏 👉 Transcriptomic & metabolic insights into #hyperammonemia: The complementary therapeutic roles of #TLR4 inhibitor (#TAK242) + ornithine phenylacetate 👍 In A-TANGO, we use #TAK242 + G-CSF

🎬 Summary #movie of A-TANGO's Investigator & Industry Session 🥂 at #EASLCongress. Big thanks to Yaqrit for sponsoring this inspiring event. Let's roll up our sleeves now to start the #GTAK trial in the UK, and hopefully also in India + Germany & other EU countries 🩺 ☺️! #ACLF #cirrhosis #LiverFailure

📣 Today: #POSTER TOP-203, congrats 🥳 A rising international star is A-TANGO #YoungInvestigator Wenting Tan, UCL 👉 Recombinant insulin-like growth factor-1 #IGF1: a novel therapy for #patients with #cirrhosis + #ACLF 👉 Topic: Cirrhosis & Complications #LiverFailure #ACLF @rajivjalan.bsky.social

📣 Another top-notch #poster at the very heart of A-TANGO is THU-180-YI by Supachaya Sriphoosanaphan, UCL 👉 #TLR4 inhibition restores cytochrome C oxidase mitigating #hyperammonemia-induced hepatocyte mitochondrial dysfunction #Cirrhosis & Complications #ACLF #LiverFailure @rajivjalan.bsky.social

📣 Two fantastic #posters today - visit them before 5 pm! Both by Supachaya Sriphoosanaphan, UCL 👉 THU-182 Transcriptomic and metabolic insights into #hyperammonemia: the complementary therapeutic roles of #TLR4 inhibitor and ornithine phenylacetate 👉 #Cirrhosis & Complications #ACLF #LiverFailure

TODAY - catering provided🍎🥂 - just come by - still spots open, no registration needed ✅ A-TANGO #Investigator & #Industry Session 👉 Thurs, 8 May 👉 5-7 pm at #EASLCongress 🚨 Important: Access Room D202, Elicium Building (level 2), via bridge from main level #ACLF #cirrhosis #LiverFailure #GTAK

🎙️ Talking #ACLF with #patients! The A-TANGO Layman Event at #EASL2025 hit the sweet spot between science & lived experience 🧪 New solutions via the combinatorial G-TAK therapy are on the horizon to achieve the best possible care for #LiverPatients @europeliver.bsky.social @rajivjalan.bsky.social

👏 Our superstar Julian Pohl (Charité) is not only active in ACLF research but also brings 🧪 #suPAR & #MASLD into the spotlight! His poster WED-437 at #EASLCongress this year shows it can identify at-risk patients - a game-changer for non-invasive #diagnostics. #LiverDisease #biomarkers #metabolism

Have a glimpse at Wednesday's A-TANGO highlights at #EASLCongress in Amsterdam! 🤩 #ACLF #cirrhosis #PatientAdvocacy #PatientEvent #hepatology #GTAK #CombinatorialTherapy #MASLD #HealthcareDisparities @europeliver.bsky.social @easlnews.bsky.social @rajivjalan.bsky.social @korenjak.bsky.social

Hope for #ACLF patients is on the horizon! Join the A-TANGO Patient Event at #EASLCongress: 📅 Wed, 7 May 2025 🕑 14:00–15:00 📍 Room D202, Elicium Building, Level 2 Learn about A-TANGO, the G-TAK trial and join the discussion on improving #patient outcomes. #LiverDisease @europeliver.bsky.social

Let’s talk #inflammation, #alcohol-related #hepatitis and new treatment strategies at #EASLCongress 👉 A-TANGO Networking Session 🗓️ Sat, 10 May 2025, 9:45–10:15 📍 Cirrhosis & Complications Track Hub These short networking sessions are lots of fun! @easlnews.bsky.social #hepatology #cirrhosis #ACLF

👉 Please register now: docs.google.com/forms/d/e/1F... Join us for the A-TANGO #Investigator & #Industry Session on Thursday, 8 May, from 5-7 pm at #EASLCongress. You can participate in person or online (Zoom Link will be set via email). #cirrhosis #LiverFailure #GTAK ✔️ Food & drinks provided 🥂

👏 Whohoo! More than 300 experts from 140 organisations in 38 countries have joined the Liver Health Helix. Launched in 2021 to support A-TANGO's dissemination and impact, it is a community of #hepatology #LiverDisease #cirrhosis & #bioinformatics specialists. Join now: platform.crowdhelix.com/login

🩺 Who conducted the 1st #ClinicalTrial can be debated, but historical records suggest it happened in biblical times. Cornelius Engelmann (Charité), who supervises A-TANGO's clinical #GTAK trial, held an all-encompassing #Masterclass on Wed, 26 March 2025. #LiverFailure #ACLF #CombinatorialTherapy